ARKK vs BIO
ARK Innovation ETF (ARKK) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
ARK Innovation ETF (ARKK) common stock listed on US.
BIO (BIO) common stock.
ARKK does not have a complete income-statement cache yet.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
ARKK currently screens at market cap $0. BIO currently screens at market cap $0.
Not investment advice. Open the ARKK and BIO stock pages for the full models.
Not investment advice.